The diagnosis, management, and treatment of patients with bladder cancer is rapidly evolving due to advances in genetic/molecular testing and new drug development. Incorporating these scientific advancements into clinical care for both muscle invasive (MIBC) and non-muscle invasive (NMIBC) as well as upper tract urothelial cancer (UTUC) is often challenging as there are a growing number of treatment options while also facing various regulatory and payor specific hurdles particularly in the United States. Unfortunately, Level I evidence is not always available to answer many questions such as around drug sequencing, innovative approaches, and special circumstances.
The IBCU 2023 Expert Forum is a closed-format, invitation only event that will bring together a multi-disciplinary group of academic and community bladder cancer experts to discuss and debate the most challenging questions in all areas of bladder cancer. The meeting will be held December 1-3, 2023 in Washington, D.C., immediately following Society of Urologic Oncology annual meeting. A faculty of 30 bladder experts will discuss the latest clinical data and real-world clinical evidence to determine the impact on management of patients with bladder cancer. Multiple interactive sessions will be designed by national experts in the field to cover the most thought-provoking and contemporary questions facing the oncology community today. Each session will include open debate and discussion followed by formal voting by the multidisciplinary panelists. A peer-reviewed article is planned for publishing the consensus statement of the findings from the IBCU 2023 Expert Forum.